The Women’s Tennis Association (WTA) has implemented a new transgender eligibility policy requiring players to undergo mandatory genetic testing to compete in the women’s category. The policy, announced last month, mandates that athletes submit to a one-time screening for the SRY gene, located on the Y chromosome, to verify eligibility. Players must also sign documentation acknowledging that refusal to comply could result in disciplinary action.
World No. 1 Aryna Sabalenka publicly endorsed the policy during a press conference at the Canadian Open in Montreal. Sabalenka stated that the measure is necessary to maintain fairness in women’s tennis, emphasizing the biological differences between men and women. “Biologically, men are way stronger than women, so I feel like it would not really be fair for women to compete against biological men,” she said. Sabalenka added that she would willingly undergo the testing herself, calling the requirement “pretty fair.”
The WTA’s previous policy allowed transgender women to compete in the women’s category if they maintained testosterone levels below a specified threshold. The updated rules now require genetic verification as an additional safeguard. Players who test positive for the SRY gene will undergo further medical assessment before being cleared to compete. The policy applies to all WTA players and is framed as a step to protect the integrity of the women’s tour.
Sabalenka’s endorsement aligns with broader debates in sports governance regarding the inclusion of transgender athletes in elite women’s competitions. The WTA’s decision follows similar moves by other sporting organizations to implement genetic testing as part of eligibility protocols. The policy has drawn both support and criticism, with advocates arguing it ensures fairness and opponents contending it excludes transgender women from participation.
The WTA did not immediately respond to requests for additional details on the implementation timeline or the number of players expected to undergo testing. The organization has stated that the policy is designed to uphold the foundational principle of women’s sports: that biological sex distinctions are relevant to competition.
Sabalenka, a Belarusian player, has previously participated in mixed-gender exhibition matches, including a December 2023 “Battle of the Sexes” event in Dubai against Nick Kyrgios. Her public stance on the policy reflects a growing trend among high-profile athletes to weigh in on the issue, often citing concerns about competitive fairness.
The WTA’s policy change comes amid ongoing discussions within international sports federations about how to balance inclusion with the preservation of women’s sports as spaces for biological females. The International Olympic Committee and other governing bodies have issued non-binding guidelines, leaving individual sports to determine their own eligibility standards. The WTA’s decision to adopt genetic testing marks a definitive shift toward a more restrictive approach in tennis.
Critics of the policy argue that it could set a precedent for further exclusions in other sports, while supporters contend that it is a necessary measure to protect the integrity of women’s competitions. The policy’s long-term impact on athlete participation and public perception of transgender inclusion in sports remains uncertain.